Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Kiromic Biopharma Inc
(NQ:
KRBP
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 13, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kiromic Biopharma Inc
< Previous
1
2
3
Next >
Kiromic BioPharma, Inc. (NASDAQ:KRBP) Investor Notice: Investigation over Possible Violations of Securities Laws
April 11, 2022
San Diego, CA -- (SBWIRE) -- 04/11/2022 -- Kiromic BioPharma, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights
April 08, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic Biopharma Announces Filing of Form 12b-25
April 01, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Announces Changes in Management, Board of Directors
February 03, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to Company’s Board of Directors
February 03, 2022
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid Tumors
October 25, 2021
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Announces Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allogeneic CAR-T Clinical Trial Candidate Alexis ISO-1 in Solid Cancers
October 11, 2021
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Announces Chief Financial Officer Transition
October 05, 2021
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Operating Highlights
August 13, 2021
From
Kiromic BioPharma
Via
Business Wire
Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance Clinical Development on Its Outpatient Allogeneic CAR-T for Solid Tumors
July 26, 2021
From
Kiromic Biopharma, Inc.
Via
Business Wire
Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors
July 16, 2021
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma, Inc. Announces Closing of Public Offering
July 02, 2021
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma, Inc. Announces Pricing of Public Offering
June 29, 2021
From
Kiromic BioPharma, Inc.
Via
Business Wire
KRBP Presenting at 2021 Next-Gen Immuno Oncology Congress Showcasing Its Proprietary AI Targets for Off-the-Shelf Allogenic CAR-T for Solid Tumors
June 28, 2021
From
Kiromic Biopharma, Inc.
Via
Business Wire
KRBP Presenting at July 2021 Gamma Delta T Cell Summit to Showcase Our Off-The-Shelf Allogeneic Gamma Delta T Cell Therapy
June 17, 2021
From
Kiromic Biopharma, Inc.
Via
Business Wire
Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as Chief Operating and Manufacturing Officer
June 07, 2021
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter
May 24, 2021
From
Kiromic Biopharma, Inc.
Via
Business Wire
Kiromic Announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine
May 21, 2021
From
Kiromic Biopharma, Inc.
Via
Business Wire
Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy
May 17, 2021
From
Kiromic Biopharma, Inc.
Via
Business Wire
Kiromic BioPharma Reports First Quarter 2021 Financial Results and Continued Corporate Progress
May 14, 2021
From
Kiromic BioPharma
Via
Business Wire
Kiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intelligence (AI) Biomarker Engine
May 03, 2021
From
Kiromic BioPharma, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.